抗CTGF寡核苷酸降低术后增生性瘢痕严重程度:随机双盲自身对照安慰剂研究
一项随机、双盲、自身对照、安慰剂对照研究纳入23例28至55岁双侧对称乳房增生性手术瘢痕女性,瘢痕修整术后切口随机接受EXC 001(5 mg/cm)或安慰剂皮内注射(第2、5、8、11周)。第12和24周评估显示EXC 001在专家面板、医师和患者三种测量中均显著降低瘢痕严重程度。
要点
- EXC 001(5 mg/cm)皮内注射可显著降低乳房术后增生性瘢痕严重程度。
- 第12和24周专家面板与医师POSAS评估p<0.001,患者POSAS p<0.003。
- 抑制CTGF可能是增生性瘢痕治疗的可行策略,支持进一步研究。
核心结论
- EXC 001皮内注射可显著降低瘢痕修整术后皮肤瘢痕的严重程度,抑制CTGF可能是增生性瘢痕减低的可行策略,支持进一步研究该反义寡核苷酸。
研究设计与样本
- 随机、双盲、自身对照、安慰剂对照研究,纳入23例28至55岁双侧对称乳房增生性手术瘢痕女性,行瘢痕修整术后将切口随机分配至EXC 001(5 mg/cm)或安慰剂皮内注射,于术后第2、5、8、11周给药。
主要发现
- EXC 001在瘢痕修整术后第12和24周在全部三种测量中均显著降低瘢痕严重程度:专家面板和医师POSAS p<0.001,患者POSAS p<0.003。
关键数值与推荐
- EXC 001剂量为5 mg/cm,于术后第2、5、8、11周皮内注射。
- 瘢痕严重程度于第12和24周由专家面板基于盲法照片、医师和受试者采用POSAS评估。
- 专家面板和医师POSAS评估p<0.001,患者POSAS评估p<0.003。
临床怎么用
- 对于乳房增生性手术瘢痕修整术后患者,可考虑皮内注射靶向CTGF的反义寡核苷酸EXC 001(5 mg/cm)以降低后续瘢痕严重程度。
局限性
- 研究为初步数据,样本量23例,仅纳入女性乳房对称性增生性瘢痕,设计假设自身内变异较小并通过随机化控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Connective tissue growth factor (CTGF) levels are up-regulated in wounded skin and are thought to play a major role in scar formation. An antisense oligonucleotide targeting CTGF was evaluated in adult patients undergoing hypertrophic scar revision surgery, to determine effects on reducing the severity of subsequent scars. METHODS: In a randomized, double-blind, within-subject, placebo-controlled study, 23 female subjects (aged 28 to 55 years) with bilateral, symmetric, hypertrophic surgical scars of the breast underwent scar revision surgery. The resulting breast incisions were randomized to receive EXC 001 (5 mg/cm) or placebo injected intradermally at postsurgery weeks 2, 5, 8, and 11. Scar severity assessments were performed at weeks 12 and 24 by an expert panel using blinded photographs, and by physicians and subjects using a scar scoring scale, the Patient and Observer Scar Assessment Scale. An assumption of the design is that within-subject variance would be small and that whatever within-subject variance there was would be controlled through the randomization process. RESULTS: EXC 001 significantly reduced scar severity at both 12 and 24 weeks after scar revision surgery in all three measures (expert panel and physician Patient and Observer Scar Assessment Scale, p < 0.001; Patient and Observer Scar Assessment Scale, p < 0.003). CONCLUSIONS: This study provided positive preliminary data that intradermal injection of EXC 001 produced a significant reduction in severity of postsurgical skin scars, as measured by physicians, subjects, and an expert panel. This study provided evidence that suppression of CTGF could be a viable strategy for hypertrophic scar reduction therapy and that further study of the antisense oligonucleotide EXC 001 was indicated. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Jensen J, Gentzkow G, Berman G, et al. Anti-CTGF Oligonucleotide Reduces Severity of Postsurgical Hypertrophic Scars in a Randomized, Double-Blind, Within-Subject, Placebo-Controlled Study. Plast Reconstr Surg. 2018. PMID: 30045185. doi:10.1097/PRS.0000000000004590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。